Schering, a German pharmaceuticals company, is hoping to get approval for a contrast agent whose bubbles, under a correctly tuned ultrasonic beam, will oscillate and eventually rupture.

ECONOMIST: The ne plus ultra of medicine

The first such agent to gain U.S. Food and Drug Administration approval was Seattle Genetics Inc.

WSJ: Roche Breast-Cancer Treatment Advances